Sign In
Buy AMRX
$18.09
+0.170 (+0.95%)
At Close: Jul 27, 2026
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates
08:15am, Friday, 09'th Aug 2024
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.19 per share a year ago.
Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q2 Earnings
10:20am, Wednesday, 07'th Aug 2024
Get a deeper insight into the potential performance of Amneal (AMRX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some o
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q2 Earnings Expected to Decline
11:01am, Friday, 02'nd Aug 2024
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) is a Great Momentum Stock: Should You Buy?
01:00pm, Monday, 29'th Jul 2024
Does Amneal Pharmaceuticals (AMRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
10:40am, Monday, 29'th Jul 2024
Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Amneal (AMRX) Is Attractively Priced Despite Fast-paced Momentum
09:51am, Monday, 29'th Jul 2024
Amneal (AMRX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading
Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success
11:40am, Wednesday, 10'th Jul 2024
Amneal Pharmaceuticals has seen a significant increase in its share price of >400% after hitting an all-time low in March 2023. The company reported record revenues in Q1 2024, with growth in all thre
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
04:05pm, Tuesday, 09'th Jul 2024
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced the launch of FOCINVEZ™, a ready-to-use injectable. Unlike other v
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
08:00am, Wednesday, 05'th Jun 2024
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the continued expansion of its injectables portfolio with six new in
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
04:05pm, Wednesday, 22'nd May 2024
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California.
Amneal to Participate at Upcoming Investor Conference
04:05pm, Wednesday, 22'nd May 2024
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conference.
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Earnings Call Transcript
01:37pm, Friday, 03'rd May 2024
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2024 Results Earnings Conference Call May 3, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co
Drugmaker Amneal agrees to $270 million U.S. opioid settlement
11:00am, Friday, 03'rd May 2024
Amneal Pharmaceuticals said on Friday it had reached a deal valued at more than $270 million to resolve claims it helped fuel the deadly U.S. opioid epidemic, becoming the latest drug company to settl
Amneal (AMRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
10:36am, Friday, 03'rd May 2024
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street e
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
08:11am, Friday, 03'rd May 2024
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.
